 | ||||||||||||
| ||||||||||||
| ||||||||||||
| ||||||||||||
 | ||||||||||||
 | ||||||||||||
 | ||||||||||||
| ||||||||||||||||||||
 Click here to watch the Mechanism of Action video |
|
 Marqibo® (vincristine sulfate liposomes injection, OPTISOME™) A Novel Targeted Nanoparticle-encapsulated Anti-Cancer Compound currently for Acute Lymphoblastic Leukemia (ALL) and Melanoma. Marqibo® has a robust safety database (over 600 patients) and has been extensively evaluated in lymphoid blood cancers such as non-Hodgkin’s lymphoma (NHL) and ALL. Hana has ongoing (or planned) clinical trials which may enable an accelerated approval in 2 indications. Future clinical trial development possible in multiple indications including NHL and melanoma. More Details » Alocrest™ (vinorelbine liposomes injection, OPTISOME™) A Novel Targeted Anti-Cancer Compound for Breast and Lung Cancer. Alocrest™ has completed a Phase I dose-escalation trial demonstrating promising anti-cancer activity as well as acceptable and predictable toxicity. More Details » Brakiva™ (topotecan liposomes injection, OPTISOME™) A Novel Targeted Anti-Cancer Compound for Small-Cell Lung Cancer and Ovarian Cancer. Preclinical data demonstrate the value of Brakiva™ over conventional topotecan. More Details » Menadione Topical Lotion - A Topical Compound for Skin Rash Associated with EGFR Inhibitors. Treatment with EGFR inhibitors such as Tarceva®, Erbitux® and Vectibix® are associated with an acne-form rash involving the face, neck and upper torso in approximately 75% patients. 50% of patients who manifest skin toxicity experience significant discomfort. This results in drug discontinuation or dose reduction in at least 10% and up to 30% of all subjects. Drug delivery is targeted to the normal location of the EGFR-containing skin cells at the dermal/epidermal junction without interfering with EGFR inhibition systemically at the level of the tumor. More Details » For further information on our product pipeline and/or business development inquiries please contact the Business Development Department. |
||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
